AIM ImmunoTech Inc. (AIM), Wednesday revealed 15 times increase in incidence of Myalgic encephalomyelitis or ME/ Chronic Fatigue Syndrome or CFS in patients infected with SARS-CoV-2.
The RECOVER-Adult study found that 73 post-COVID patients out of 4515 participants developed ME/CFS in at least six months time. The prevalence was 4.5 percent, nearly eight times higher than the uninfected participants. The study published in the Journal of General Internal Medicine noted that the prevalence is five times higher than pre-pandemic estimates and underscores the severe and lasting impact of COVID-19 on public health.
Currently, AIM's stock is trading at $0.22, up 2.60 percent on the New York Stock Exchange American.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.